Blueprint’s Ayvakit picks up long-awaited FDA approval in indolent systemic mastocytosis zbecker Mon, 05/22/2023 – 14:43 More: Blueprint's Ayvakit picks up long-awaited FDA approval in indolent systemic mastocytosis Source: fierce
read moreBayer’s blockbuster hopeful Nubeqa, AstraZeneca’s Forxiga pick up nods from England’s NICE zbecker Mon, 05/22/2023 – 10:44 More: Bayer's blockbuster hopeful Nubeqa, AstraZeneca's Forxiga pick up nods from England's NICE Source: fierce
read moreWith Dupixent leading the way, Sanofi’s taking on the ‘big players’ in respiratory diseases: exec kdunleavy Mon, 05/22/2023 – 07:33 More: With Dupixent leading the way, Sanofi’s taking on the 'big players' in respiratory diseases: exec Source: fierce
read moreTreatment involves early Alzheimer’s disease and will be potentially used across Great Britain More: Eisai makes lecanemab therapy application Source: News
read moreNovo Nordisk pauses Wegovy marketing projects to dampen demand badams Mon, 05/22/2023 – 07:14 More: Novo Nordisk pauses Wegovy marketing projects to dampen demand Source: fierce
read moreACD856 is the leading candidate therapy on the company’s NeuroRestore platform More: Vital patent for AlzeCure Alzheimer’s drug Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals